Search

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

Press release

… Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, 2018 … the two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis …

January 08, 2018
ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology

Press release

Key program features and updates:

June 15, 2017
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

Press release

LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 30, 2018
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

Press release

Key updates

September 21, 2017
ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Press release

Key Updates

April 10, 2018
Today marks an expansion of the ProQR and Lilly partnership

News update

Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.

December 22, 2022
ProQR Therapeutics Virtual R&D Event 2023

Webcast

On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.

March 29, 2023
ProQR Analyst Event

Webcast

During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

November 18, 2021
“A new way of designing medicines”

Story

Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.

March 30, 2018
Unlocking the Potential of Innovative Editing Oligonucleotides (EONs) to Address Liver Originated Disorders

Presentation

The presentation reviews EONs structure activity, the potential of the Axiomer platform as well as its applicability for the treatment of liver originated disorders. Presented at TIDES USA on May 9, 2023 by Gerard Platenburg - ProQR Therapeutics.

May 09, 2023